Kraft to Collaborate With Medisyn on Discovering Bioactives

Medisyn Technologies collaborates with Kraft Foods to drive discovery of effective bioactive ingredients suitable for food use.

15/01/09 Medisyn Technologies, Inc., announced a research and licensing collaboration with Kraft Foods Global Inc. to discover effective bioactive ingredients suitable for food use.  The work, which began in December, 2008, utilizes Medisyn’s Forward Engineering technology platform to identify, analyze and optimize promising bioactive compounds. This technology accurately predicts how a compound will behave based on its structure, greatly streamlining the discovery and development process of food ingredients that can be used to provide healthier choices for consumers.

“Kraft is on the leading edge of delivering wholesome and delicious foods to consumers,” said David Land, president of Medisyn. “We’re confident our experience will be an asset as we work together to capitalize on the growing role functional foods will play among today’s 76 million aging Baby Boomers.”

Land noted that more than half of all Americans say they are making significant efforts to eat better to maintain health and manage disease conditions, including obesity, diabetes, high cholesterol, osteoporosis and high blood pressure. As these demographic trends continue, the global functional foods market is expected to grow to $90.5 billion by 2013, according to Just-Food's 2008 Global Market Review of Functional Foods.

"Helping consumers achieve better nutritional balance and manage health is an important food trend," said Todd Abraham, Senior Vice President, Nutrition & Research, Kraft Foods. "We're excited and optimistic about our collaborations with Medisyn and the potential its technology offers to make significant discoveries in bioactive ingredients suitable for food use to address these needs."

Currently, Medisyn is engaged in more than 30 related research projects.  Medisyn has also worked with leading institutions including Mount Sinai School of Medicine, The U.S. Department of Defense and Invitrogen, among others.

The collaboration covers bioactive discovery with development and commercialization milestones as well as post-commercialization payments.